Accuray Incorporated (NASDAQ:ARAY) Shares Bought by Fmr LLC

Fmr LLC boosted its holdings in Accuray Incorporated (NASDAQ:ARAY) by 27.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 582,591 shares of the medical equipment provider’s stock after purchasing an additional 124,459 shares during the quarter. Fmr LLC’s holdings in Accuray were worth $1,049,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ARAY. Nisa Investment Advisors LLC grew its stake in shares of Accuray by 253,483.3% in the second quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 15,209 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Accuray during the 2nd quarter valued at $30,000. US Bancorp DE lifted its stake in shares of Accuray by 1,087.7% in the third quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 16,316 shares in the last quarter. Caprock Group LLC purchased a new position in Accuray in the third quarter valued at about $36,000. Finally, Intech Investment Management LLC acquired a new position in shares of Accuray in the 3rd quarter valued at approximately $41,000. 64.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $1.95 on Tuesday. The company has a quick ratio of 0.87, a current ratio of 1.63 and a debt-to-equity ratio of 3.59. The firm has a 50-day simple moving average of $1.91 and a 200 day simple moving average of $1.88. The company has a market cap of $196.10 million, a PE ratio of -11.47 and a beta of 1.44. Accuray Incorporated has a fifty-two week low of $1.40 and a fifty-two week high of $3.05.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. The company had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. On average, sell-side analysts anticipate that Accuray Incorporated will post 0.01 EPS for the current year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.